Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 2 Erlotinib Monotherapy in Pediatric Recurrent or Refractory Ependymoma After Oral Etoposide (OSI-774-205 Extension)
2010-023478-38Phase 2Completed
- Sponsor
- OSI Pharmaceuticals
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in ependymoma, sponsored by OSI Pharmaceuticals. Primary endpoint: Safety profile of single-agent erlotinib. Started Jan 2011; status: completed.
02
Drugs
erlotinib
03
Conditions
ependymoma
Beyond the preview
Go deeper on 2010-023478-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023478-38.